Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer

Journal of Nuclear Medicine

Volumn 53, Issue 7, 2012, Pages 1119-1126

  Fowler, Amy M ^a   Chan, Szeman Ruby ^b   Sharp, Terry L ^a   Fettig, Nicole M ^a   Zhou, Dong ^a   Dence, Carmen S ^c   Carlson, Kathryn E ^c   Jeyakumar, M ^c   Katzenellenbogen, John A ^c   Schreiber, Robert D ^b   Welch, Michael J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Breast cancer; Endocrine therapy; Estrogen receptor; PET imaging; Progesterone receptor

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; FLUORO FURANYL NORPROGESTERONE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROESTRADIOL F 18; FULVESTRANT; GESTAGEN; LETROZOLE; PROGESTERONE RECEPTOR; RADIOPHARMACEUTICAL AGENT; STAT1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONCENTRATION (PARAMETERS); DRUG EFFICACY; FEMALE; GLUCOSE TRANSPORT; HORMONAL THERAPY; IN VITRO STUDY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, WESTERN; CELL LINE, TUMOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; FLUORODEOXYGLUCOSE F18; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; NORPREGNENES; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RABBITS; RADIOPHARMACEUTICALS; RECEPTORS, STEROID; STAT1 TRANSCRIPTION FACTOR;

EID: 84863428572     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.103465     Document Type: Article

References (34)

1. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233-247.
2. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134:e48-e72.
3. Kuukasjärvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol. 1996;14:2584-2589. (Pubitemid 26300127)
4. Liedtke C, Broglio K, Moulder S, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009;20:1953-1958.
5. Katzenellenbogen JA, Welch MJ, Dehdashti F. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res. 1997;17:1573-1576. (Pubitemid 27263124)
6. 18F]fluoro-17beta-estradiol. J Med Chem. 2005;48:6366-6378.
7. Kiesewetter DO, Kilbourn MR, Landvatter SW, Heiman DF, Katzenellenbogen JA, Welch MJ. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med. 1984;25:1212-1221. (Pubitemid 15214135)
8. 18F]fluoro)-17 beta-estradiol in DMBA-induced mammary tumors. Int J Rad Appl Instrum B. 1987;14:15-25.
9. Mintun MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors. Radiology. 1988;169:45-48.
10. Peterson LM, Mankoff DA, Lawton T, et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med. 2008;49:367-374. (Pubitemid 351355201)
11. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995;36:1766-1774.
12. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001;19:2797-2803. (Pubitemid 32538187)
13. Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24:2793-2799. (Pubitemid 46630578)
14. Buckman BO, Bonasera TA, Kirschbaum KS, Welch MJ, Katzenellenbogen JA. Fluorine-18-labeled progestin 16 alpha, 17 alpha-dioxolanes: development of high-affinity ligands for the progesterone receptor with high in vivo target site selectivity. J Med Chem. 1995;38:328-337.
15. 18F-fluoro-16alpha, 17alpha-[(R)-(1′-alphafurylmethylidene) dioxy]-19-norpregn-4-ene-3,20- dione. J Nucl Med. 2012;53: 363-370.
16. Meraz MA, White JM, Sheehan KC, et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell. 1996;84:431-442. (Pubitemid 26058568)
17. Chan SR, Vermi W, Luo J, et al. STAT1-deficient mice spontaneously develop estrogen receptor alpha-positive luminal mammary carcinomas. Breast Cancer Res. January 20, 2012 [Epub ahead of print].
18. Vijaykumar D, Mao W, Kirschbaum KS, Katzenellenbogen JA. An efficient route for the preparation of a 21-fluoro progestin-16 alpha,17 alpha-dioxolane, a highaffinity ligand for PET imaging of the progesterone receptor. J Org Chem. 2002;67:4904-4910. (Pubitemid 34742724)
19. Zhou D, Dence CS, Katzenellenbogen JA, Welch MJ. Synthesis of [F-18]fluoro furanyl norprogesterone (FFNP) for clinical evaluation as a PET imaging agent for progesterone receptor (PR) in breast tumors [abstract]. J Labelled Comp Radiopharm. 2011;54(suppl):S497.
20. Lim JL, Zheng L, Berridge MS, Tewson TJ. The use of 3-methoxymethyl-16 beta, 17 beta-epiestriol-O-cyclic sulfone as the precursor in the synthesis of F-18 16 alpha-fluoroestradiol. Nucl Med Biol. 1996;23:911-915. (Pubitemid 26392233)
21. 18F]fluoro-17 beta-estradiol (FES) metabolite analyses in rodent tissue micro samples by solid-phase (SP) Florisil columns [abstract]. J Nucl Med. 2011;52 (suppl 1):298P.
22. Qi J, Leahy RM, Cherry SR, Chatziioannou A, Farquhar TH. High-resolution 3D Bayesian image reconstruction using the microPET small-animal scanner. Phys Med Biol. 1998;43:1001-1013. (Pubitemid 28168428)
23. Saji S, Sakaguchi H, Andersson S, Warner M, Gustafsson J. Quantitative analysis of estrogen receptor proteins in rat mammary gland. Endocrinology. 2001;142: 3177-3186. (Pubitemid 32575555)
24. Katzenellenbogen JA, Heiman DF, Carlson KE, Lloyd JE. In vitro and in vivo steroid receptor assays in the design of estrogen radiopharmaceuticals. In: Eckelman W, ed. Receptor Binding Radiotracers. Vol 1. Boca Raton, FL: CRC Press; 1982:93-126.
25. Sullivan WP, Smith DF, Beito TG, Krco CJ, Toft DO. Hormone-dependent processing of the avian progesterone receptor. J Cell Biochem. 1988;36:103-119.
26. Fatum M, Gyo Y, Diana P, Laufer N, Simon A. Is estradiol mandatory for an adequate follicular and embryo development? A mouse model using aromatase inhibitor (anastrozole). J Assist Reprod Genet. 2006;23:407-412. (Pubitemid 46020542)
27. Howell A. Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr Relat Cancer. 2006;13:689-706. (Pubitemid 44763252)
28. Aliaga A, Rousseau JA, Ouellette R, et al. Breast cancer models to study the expression of estrogen receptors with small animal PET imaging. Nucl Med Biol. 2004;31:761-770. (Pubitemid 38887758)
29. Downer JB, Jones LA, Katzenellenbogen JA, Welch MJ. Effect of administration route on FES uptake into MCF-7 tumors. Nucl Med Biol. 2001;28:397-399. (Pubitemid 32520998)
30. Linden HM, Kurland BF, Peterson LM, et al. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res. 2011;17:4799-4805.
31. 18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med. 1991;32:1526-1531.
32. Dehdashti F, Flanagan FL,Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999;26:51-56. (Pubitemid 29137739)
33. Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771-784.
34. Howell A, Harland RN, Barnes DM, et al. Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. Cancer Res. 1987;47:300-304. (Pubitemid 17002140)